ORMP fundamentals
ORAMED PHARM financial statements, including revenue, expenses, and profit
The annual and quarterly earnings report below will help you understand the performance of ORMP.
Q4 '16
Q1 '17
Q2 '17
Q3 '17
Q4 '17
Q1 '18
Q2 '18
Q3 '18
Q4 '18
Q1 '19
Q2 '19
Q3 '19
Q4 '19
Q1 '20
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
−80.00 M
−40.00 M
0.00
40.00 M
80.00 M
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: ILS
Q4 '16
Aug 2016
Q1 '17
Nov 2016
Q2 '17
Feb 2017
Q3 '17
May 2017
Q4 '17
Aug 2017
Q1 '18
Nov 2017
Q2 '18
Feb 2018
Q3 '18
May 2018
Q4 '18
Aug 2018
Q1 '19
Nov 2018
Q2 '19
Feb 2019
Q3 '19
May 2019
Q4 '19
Aug 2019
Q1 '20
Nov 2019
Q2 '20
Feb 2020
Q3 '20
May 2020
Q4 '20
Aug 2020
Q1 '21
Nov 2020
Q2 '21
Feb 2021
Q3 '21
May 2021
Q4 '21
Aug 2021
Q1 '22
Mar 2022
Q2 '22
Jun 2022
Q3 '22
Sep 2022
Q4 '22
Dec 2022
Q1 '23
Mar 2023
Q2 '23
Jun 2023
Q3 '23
Sep 2023
Q4 '23
Dec 2023
Q1 '24
Mar 2024
Q2 '24
Jun 2024
Q3 '24
Sep 2024
TTM
Total revenueYoY growth
2.40 M
+9.52%
2.40 M
+12.69%
2.50 M
+6.24%
0.00
−100.00%
0.00
−100.00%
0.00
−100.00%
0.00
−100.00%
0.00
—
—
—
−133.38 K
−193.16 K
−206.31 K
−192.44 K
−207.05 K
−204.07 K
−194.04 K
−802.30 K
Gross profitYoY growth
—
2.27 M
—
2.31 M
—
−206.31 K
—
−192.44 K
—
−207.05 K
−109.13%
−204.07 K
−108.83%
−194.04 K
+5.95%
−802.30 K
−36.61 M
−21.04 M
−16.39 M
−10.85 M
−13.88 M
−10.74 M
−11.64 M
−11.33 M
−47.94 M
Operating incomeYoY growth
−34.28 M
−44.38%
−18.77 M
+47.84%
−14.08 M
+64.72%
−11.05 M
+62.12%
−14.08 M
+58.93%
−10.95 M
+41.67%
−11.85 M
+15.87%
−11.53 M
−4.29%
−48.75 M
3.53 M
5.76 M
9.20 M
−1.49 M
62.35 M
16.62 M
52.81 M
−57.54 M
83.16 M
Pretax incomeYoY growth
−30.74 M
−33.53%
−13.02 M
+62.00%
−4.88 M
+87.40%
−12.55 M
+50.78%
48.28 M
—
5.67 M
—
40.96 M
—
−69.07 M
−450.49%
26.71 M
679.17 K
778.63 K
442.03 K
236.88 K
145.24 K
7.39 K
30.23 K
85.83 K
272.41 K
−30.06 M
−12.24 M
−4.44 M
−12.31 M
48.42 M
5.68 M
34.81 M
−73.21 M
16.66 M
Net incomeYoY growth
−30.06 M
−36.93%
−12.24 M
+63.30%
−4.44 M
+87.96%
−12.31 M
+51.07%
48.42 M
—
5.68 M
—
34.81 M
—
−73.21 M
−494.73%
16.66 M
−30.06 M
−12.24 M
−4.44 M
−12.31 M
48.42 M
5.68 M
34.81 M
−73.21 M
16.66 M
Basic earnings per share (Basic EPS)YoY growth
−0.76
−13.62%
−0.31
+64.54%
−0.11
+88.38%
−0.30
+52.69%
1.20
—
0.14
—
0.85
—
−1.79
−487.87%
0.42
Diluted earnings per share (Diluted EPS)YoY growth
−0.76
−13.62%
−0.31
+64.54%
−0.11
+88.38%
−0.30
+52.69%
1.20
—
0.14
—
0.84
—
−1.79
−487.87%
0.41
39.47 M
40.04 M
40.23 M
40.45 M
40.34 M
40.84 M
40.96 M
40.90 M
—
39.47 M
40.04 M
40.23 M
40.45 M
40.38 M
41.56 M
41.59 M
40.90 M
—
EBITDAYoY growth
−34.22 M
−44.50%
−18.64 M
+48.16%
−13.89 M
+65.16%
−10.85 M
+62.76%
−13.88 M
+59.42%
−10.74 M
+42.36%
−11.64 M
+16.17%
−11.33 M
−4.48%
−47.94 M
EBITYoY growth
−34.28 M
−44.38%
−18.77 M
+47.84%
−14.08 M
+64.72%
−11.05 M
+62.12%
−14.08 M
+58.93%
−10.95 M
+41.67%
−11.85 M
+15.87%
−11.53 M
−4.29%
−48.75 M
−36.67 M
−21.17 M
−16.59 M
−11.05 M
−14.08 M
−10.95 M
−11.85 M
−11.53 M
−48.75 M